Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury by Citrin, Deborah et al.
Radioprotectors and Mitigators of Radiation-Induced Normal
Tissue Injury
DEBORAH CITRIN,
a ANA P. COTRIM,
c FUMINORI HYODO,
b BRUCE J. BAUM,
c MURALI C. KRISHNA,
b
JAMES B. MITCHELL
b
aRadiation Oncology and
bRadiation Biology Branches, Center for Cancer Research, National Cancer
Institute and
cMolecular Physiology and Therapeutics Branch, National Institute of Dental and
Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
Key Words. Radioprotector • Mitigators • Amifostine • Tempol
Disclosures: Deborah Citrin: None; Ana P. Cotrim: None; Fuminori Hyodo: None; Bruce J. Baum: None; Murali C.
Krishna: None; James B. Mitchell: None.
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from
commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent
peer reviewers.
ABSTRACT
Radiation is used in the treatment of a broad range of ma-
lignancies. Exposure of normal tissue to radiation may re-
sult in both acute and chronic toxicities that can result in
an inability to deliver the intended therapy, a range of
symptoms, and a decrease in quality of life. Radioprotec-
tors are compounds that are designed to reduce the dam-
age in normal tissues caused by radiation. These
compoundsareoftenantioxidantsandmustbepresentbe-
fore or at the time of radiation for effectiveness. Other
agents, termed mitigators, may be used to minimize toxic-
ity even after radiation has been delivered. Herein, we
review agents in clinical use or in development as radio-
protectorsandmitigatorsofradiation-inducednormaltis-
sue injury. Few agents are approved for clinical use, but
many new compounds show promising results in preclin-
ical testing. The Oncologist 2010;15:360–371
INTRODUCTION
Radiotherapy is commonly used as a component of therapy
forawiderangeofmalignantconditions.Itisestimatedthat
half of all cancer patients will receive radiotherapy during
the course of their treatment for cancer [1]. Radiotherapy is
frequently used to achieve local or regional control of ma-
lignancies either alone or in combination with other modal-
ities such as chemotherapy or surgery.
Irradiation of noncancerous “normal” tissues during the
course of therapeutic radiation can result in a range of side
effects including self-limited acute toxicities, mild chronic
symptoms, or severe organ dysfunction. The likelihood of
developing these complications relates to the volume of an
organ irradiated, the radiation dose delivered, fractionation
of the delivered dose, the delivery of radiation modifiers,
and individual radiosensitivity. Efforts to reduce the toxic-
ities associated with therapeutic radiation have centered on
both technological improvements in radiation delivery and
chemical modifiers of radiation injury.
The use of technology to reduce normal tissue toxicity
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sity-modulated radiotherapy, image-guided radiotherapy,
and proton radiotherapy. Each of these aims to reduce the
volume of normal tissue exposed to high doses of radiation
compared with conventional therapies, thus reducing the
risk for normal tissue toxicity. Studies of these modalities
have shown that better normal tissue dose distributions and
side effect profiles can be obtained using these technolo-
gies. Although improvements have been realized in this re-
gard, normal tissue toxicity remains a limiting factor in the
treatment of many diseases with radiation therapy. Based
on the intimate relationship between tumors and their nor-
mal host tissues and surrounding critical structures and the
need to irradiate clinically uninvolved normal tissue mar-
ginsthatarepotentiallycontaminatedwithmicroscopicdis-
ease, it is anticipated that normal tissue toxicity will remain
a concern for therapeutic radiation.
An alternative mechanism to reduce normal tissue tox-
icity is the use of radiation modifiers/protectors, agents
that when present prior to or shortly after radiation expo-
sure alter the response of normal tissues to irradiation.
Thisapproachhasalsobeenviewedasanattractivecoun-
termeasure for possible nuclear/radiological terrorism. To
be useful in the radiotherapy clinic, radioprotectors should
ideally have several characteristics that relate to the ability
oftheagenttoimprovethetherapeuticratio.First,theagent
should be selective in protecting normal tissues from radio-
therapy without protecting tumor tissue, otherwise no ben-
efit in the therapeutic index will be realized. Second, the
agent should be delivered with relative ease and with min-
imal toxicity. Finally, the agent should protect normal tis-
sues that are considered sensitive such that acute or late
toxicitiesinthesetissuesareeitherdose-limitingorrespon-
sible for a significant reduction in quality of life (i.e., mu-
cositis, pneumonitis, myelopathy, xerostomia, proctitis,
and leukencephalopathy). Although a number of com-
pounds have been described that meet most or all of these
criteria in preclinical studies or in early clinical trials, only
amifostine is currently in clinical use. Herein, we provide a
classification of agents that are being evaluated to prevent
or treat normal tissue injury, describe the events that occur
after radiation that are responsible for the injury to normal
tissue,anddiscusssomeagentsindevelopmentasradiation
protectors and radiation mitigators.
CLASSIFICATION OF AGENTS
In general, chemical/biological agents used to alter normal
tissue toxicity from radiation can be broadly divided into
three categories based on the timing of delivery in relation
toradiation:chemicalradioprotectors,mitigators,andtreat-
ment [2]. Agents delivered prior to or at the time of irradi-
ation with the intent of preventing or reducing damage to
normaltissuesaretermedradioprotectors.Agentsdelivered
atthetimeofirradiationorafterirradiationiscomplete,but
prior to the manifestation of normal tissue toxicity, are de-
scribedasmitigatorsofnormaltissueinjury.Finally,agents
delivered to ameliorate established normal tissue toxicity
are considered treatments. There is a growing body of liter-
aturedescribingradioprotectionormitigationwithavariety
of agents after total body exposures or localized exposures.
Acompleteandexhaustivereviewoftheseagentsisoutside
the scope of this review. Herein, we briefly highlight sev-
eral classes of agents that have been described as radiation
protectors and mitigators, and attempt to focus on agents
with demonstrated or anticipated clinical usefulness for
therapeutic radiation exposures. Treatment of established
radiation normal tissue injury is outside the scope of this
work.
An understanding of the events occurring during and
shortly after irradiation of tissues and cells is important to
understanding the mechanism of action of radioprotectors
and mitigators. Figure 1 shows the sequence of events in
cells and tissues following radiation exposure. Radiation
can damage cells/tissues by both direct and indirect actions
[3]. The term “direct effects” describes radiation directly
causing irreparable damage to critical targets within the
cell,suchasDNA.Theterm“indirecteffects”describesthe
situation in which radiation interacts with other molecules
ofthecellthatarenotcriticaltargetsbutarecloseenoughto
pass on this damage, typically in the form of free radicals.
Becausemammalsarecomposedofroughly80%water,in-
direct effects involve the production of radiolysis products
of water, in particular, the hydroxyl free radical, which is a
potent oxidant capable of breaking chemical bonds, initiat-
ing lipid peroxidation, in the nano- to microsecond time-
frame [4].
AfterDNAdamagehasoccurred,anumberofprocesses
occur in the damaged cell, tissue, or organism (Fig. 1), in-
cluding activation of DNA repair, activation of signal
transduction, expression of radiation response genes, stim-
ulation of proliferation, and initiation and perpetuation of
inflammation. These pathways can be important for cell or
tissue recovery after radiation exposure but may also play a
role in the development of toxicity. Mitigators of radiation
injury may target these pathways to prevent or reduce the
expression of toxicity.
Radioprotectors: Reducing Agents/Free
Radical Scavengers
As described above, free radicals are responsible for per-
petuating a large amount of the damage cause by ionizing
radiation. Therefore, for an agent to protect cells from pri-
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thetimeofradiationandinsufficientconcentrationtocom-
pete with radicals produced through radical-scavenging
mechanisms.Manyradicalscavengersandantioxidantsex-
ist that can limit the oxidative stress induced by free radi-
cals. Superoxide dismutase (SOD), catalase, glutathione
peroxidase, and glutathione reductase are a few examples
of naturally occurring antioxidants that defend against free
radical–mediated damage, where the substrates are specific
to each enzyme. General antioxidant defense is also pro-
vided by low molecular weight antioxidants, which are hy-
drogen atom–donating reducing agents such as ascorbic
acid, tocopherols, polyphenols, and thiols such as glutathi-
one.Inthissituation,theoxidantsareneutralizedbyhydro-
gen atom donation, resulting in a less reactive or
nonreactive product from the original oxidant and a radical
product from the antioxidant, which no longer can exert
detrimental effects.
Whereas radioprotectors need to have radical-scaveng-
ing properties and can also exert general antioxidant activ-
ity, all antioxidants cannot afford radioprotection [5]. This
dichotomy may be a result of the relative reactivity of radi-
ation-induced reactive species compared with those gener-
atedunderconditionsofgeneraloxidativestress(i.e.,H2O2
exposure). Scavenging hydroxyl radicals, such as those
formed with radiation-induced damage, may be accom-
plishedbyalmostanyunsaturatedorganicmoleculeormol-
ecule capable of H atom donation. Although hydroxyl
radicals can be scavenged with equal efficiency by both ra-
dioprotectors and antioxidants, cellular and in vivo radio-
protection is observed only with radioprotectors. This
suggests that a secondary species is generated by hydroxyl
radicals and is responsible for critical target (i.e., DNA)
damage. This less reactive secondary species may not be
scavengedbyconventionalantioxidantseitherbecausethey
do not accumulate in proximity to the secondary radical or
they may not have kinetic reactivity to scavenge them ef-
fectively. Thus, thiols such as amifostine and the newly de-
veloped nitroxides have sufficient reactivity to efficiently
scavenge secondary radicals. Conversely, well-known an-
tioxidants such as vitamin C and vitamin E do not act as
classic radioprotectors.
Amifostine: A Radioprotector in Use Clinically
Sulfhydryl compounds such as cysteine and cysteamine
havelongbeenknowntoactasradioprotectorsviafreerad-
icalscavengingandHatomdonation[6,7].Sincetheinitial
description of sulfhydryl/thiol compounds as radioprotec-
tors, more effective and less toxic agents have been de-
scribed. Perhaps the best known agent in this class is
amifostine. Other agents such as N-acetyl-L-cysteine and
diethydithiocarbamate have also been described as radio-
protectors, although with lower efficacy at equitoxic doses
in mice, compared with amifostine [8].
Amifostine is a phosphorothioate that is not taken into
cells until it is dephosphorylated by alkaline phosphatase
[9]. Once dephosphorylated, the agent freely diffuses into
cellsandcanactasafreeradicalscavenger.Amifostinehas
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362 Radiation-Induced Normal Tissue Injurybeen shown to concentrate more rapidly in normal tissues
than in tumor tissues in studies of tumor-bearing animals
[10],whichisthoughttoresultfromseveralfactors,includ-
ing the effects of tumor blood flow, the acidosis of tumors,
and the lower expression of alkaline phosphatase. Addi-
tional potential mechanisms of protection have been de-
scribed, including induction of hypoxia through increased
oxygen use [11, 12] and condensation of DNA [13].
The radioprotective effects and selective concentration
of amifostine into normal tissues led to extensive preclini-
cal testing of the drug as a radioprotector and eventually to
clinical testing. Amifostine has been evaluated as a radio-
protector and chemoprotector in a large number of clinical
trials, including a number of phase III trials. Randomized
trialsofamifostineasaradioprotectorhavebeencompleted
for patients with squamous cell carcinoma of the head and
neck, non-small cell lung cancer, and pelvic malignancies.
These trials have included the use of amifostine in the set-
ting of radiation and chemoradiation, both in the definitive
andadjuvantsettings.Inthesestudies,amifostinewaseval-
uated as a mechanism to prevent or reduce acute and late
xerostomia, mucositis, dysphagia, dermatitis, pneumonitis,
proctitis, and cystitis. A number of series have also evalu-
ated tumor control as an endpoint. Although many trials
have been completed, many of the early reported series
were small, used dosing schedules that varied markedly
from one study to the next, and evaluated a heterogeneous
group of patients.
More recently, amifostine was evaluated in additional
randomized trials and was found to reduce toxicity when
added to radiotherapy [14], leading the American Society
of Clinical Oncology (ASCO) to state that amifostine may
be considered for the prevention of xerostomia during frac-
tionated radiotherapy [15, 16]. These guidelines state that
current data do not support the use of amifostine in the set-
ting of chemoradiotherapy, which has become standard
therapy in a number of settings, especially in radiotherapy
foradvancedheadandneckmalignancies.Additionally,the
2008 ASCO guidelines state that the data are insufficient to
recommend the use of amifostine to prevent mucositis as-
sociated with radiotherapy for head and neck malignancies
or esophagitis associated with chemoradiotherapy for non-
small cell lung cancer. Concerns about tumor protection
and toxicity of the agent have led to controversy regarding
the appropriate setting for its use [17].
Nitroxides: Promising Agents in Clinical Development
Amifostine is the only radioprotector currently in clinical
use. A number of other compounds are in various stages
alongthepathwayofclinicaldevelopmentasradiationpro-
tectors.Nitroxidesareamongthemostpromisingagentsfor
future use as radiation protectors. Although a number of
theseagentsareusefulinthelaboratoryasradiationprotec-
tors, not all have the requisite characteristics that allow
themtobeusedclinically.Wehighlightthedevelopmentof
nitroxides as radioprotectors and describe the current status
of their clinical development.
Our laboratory has shown that stable nitroxide free rad-
icals and their one-electron reduction products, hydroxyl-
amines, are recycling antioxidants that protect cells when
exposed to oxidative stress, including superoxide and hy-
drogen peroxide (Fig. 2) [18]. Likewise, preclinical studies
have shown that the oxidized form of a nitroxide is a radio-
protectorinbothinvitro(cellsurvival)[19]andinvivo(le-
thal total body radiation) [20] models. Although the
hydroxylamine exhibits antioxidant activity, it is incapable
of protecting against radiation damage [19]. The lead com-
pound from this class for radioprotection is tempol (4-
hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl).
As with any radioprotector, there is concern that sys-
temic administration might protect tumor as well as normal
tissue. Therefore, initial preclinical studies focused on top-
ical application of tempol with the anticipation that sys-
temic levels of the drug would be low and hence not
sufficient to protect tumor tissue. Preclinical studies in
guinea pigs revealed that topical application was effective
atpreventingradiation-inducedalopecia[21,22].AphaseI
clinical trial in patients receiving whole-brain radiotherapy
suggested that tempol may be effective at preventing radi-
ation-induced alopecia with only mild (grade I and II) tox-
icity [23]. Both the preclinical and clinical studies showed
that systemic levels of tempol were negligible following
topical application.
Subsequent preclinical studies determined if tempol
was capable of radioprotection when administered system-
ically. Figure 3A shows that tempol protects against radia-
tion-induced damage to salivary glands and does not alter
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Figure 2. Schematic diagram of nitroxide radical conversion
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livery of the agent prior to irradiation would not alter tumor
control [24]. A possible explanation for the apparent differ-
ential protection of normal as opposed to tumor tissue is
showninFigure4.Intheoxidizedform,tempolisparamag-
netic and provides T1 contrast on magnetic resonance im-
aging (MRI) [25]. Because of this unique property, the
active, radioprotective form of tempol can therefore be fol-
lowed temporally using MRI. Tumors were grown on the
neck region of a mouse that would allow a single MRI slice
to include the tumor, salivary gland area, and normal leg
muscle (Fig. 4A, 4B). As shown in Figure 4C, tempol in-
jection resulted in image enhancement, which decreased as
a function of time after injection. The decrease in tempol
MRI enhancement represents cellular reduction of tempol
tothehydroxylaminetempol-H[26],whichisnonradiopro-
tective. By following the various regions of interest out-
lined in Figure 4B, a quantitative temporal assessment of
tempol concentration in its radioprotective form in tissue
can be determined as shown in Figure 4D. This plot shows
that the rate of reduction of tempol is similar for normal
muscle and salivary gland tissue; however, it is signifi-
cantlyfasterintumortissue.Collectively,thedatashownin
Figures 3 and 4 are consistent with the hypothesis that dif-
ferential radioprotection resides in a faster reduction to the
nonradioprotective hydroxylamine in tumor than in normal
tissue [24].
These preclinical findings provide feasibility to eval-
uate tempol as a radioprotector in clinical trials for can-
cer patients treated with radiation. Coupling MRI with
such a trial would permit a novel dimension that could
provide extremely important information with respect to
the timing of tempol administration and radiation treat-
ment. For example, before radiation treatment, a pilot
tempol/MRI scan could be conducted to determine the
tempol reduction rates in tumor and normal tissues en-
compassed in the proposed treatment field. Based on the
reduction rates, the optimal timing of tempol administra-
tion with respect to radiation treatment to provide selec-
tiveradioprotectiontonormaltissuescouldbedetermined.
What is unique about this approach is that the therapeutic
agentinthiscase(tempol)canbevisualizedbyMRI.There
are few therapeutic agents used in cancer management (ex-
cluding radiolabeled agents) that can be followed by non-
invasive imaging. Before such an approach can be
considered for clinical trials, more research is required to
determineiftempolreductionratesintissueschangeduring
fractionated radiation treatment. Lastly, monitoring the
profiles of reduction/oxidation of nitroxide–hydroxyl-
amine couples may actually serve as a viable approach to
assess the global redox status in tissue using MRI and have
potential applications in various disease states resulting
from oxidative stress and inflammation.
Other Antioxidants
With the understanding that free radicals perpetuate a sig-
nificantamountofthedamagecausedbyionizingradiation,
multiple vitamin antioxidants have been tested as a method
to reduce the toxicity of radiotherapy. Antioxidant com-
pounds such as glutathione, lipoic acid, and the antioxidant
vitamins A, C, and E have been evaluated in this context. A
great deal of preclinical and clinical information has been
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Figure 3. Mice were exposed to local fractionated radiation
treatment to the salivary glands (A) or tumor-bearing leg (B)
with and without systemic tempol (TP) administration (275
mg/kg given 10 minutes prior to each radiation fraction).
Note that the same TP dose and timing were used in each
study. (A): Saliva production 2 months postradiation for
miceexposedto5dailyfractionsof6Gy.Inadditiontosys-
temicdeliveryofTP,micewerealsotreatedtopicallyfor20
minutes prior to radiation with a TP gel formulation. (B):
Radiation tumor (SCCVII) regrowth study for local frac-
tionated radiation treatment with and without systemic TP
administration. Tumors received 5 daily fractions (Monday
to Friday) of 3 Gy.
Adapted from Cotrim AP, Hyodo F, Matsumoto K et al.
Differential radiation protection of salivary glands versus tu-
morbyTempolwithaccompanyingtissueassessmentofTem-
polbymagneticresonanceimaging.ClinCancerRes2007;13:
4928–4933, with permission.
364 Radiation-Induced Normal Tissue Injuryaccumulated that describes the effects of combining radio-
therapy with antioxidants. In general, the efficacy of these
naturally occurring agents as radioprotectors is less than
that for the synthetic agents previously described. It is im-
portant to briefly review the available literature on the ra-
dioprotectiveabilitiesofotheravailableantioxidantsandto
understandtheimportantimplicationsofusingtheseagents
during the course of radiotherapy.
One of the major concerns with the use of supplemental
nutritive antioxidants or other antioxidants during the
courseofradiotherapyisthepossibilityoftumorprotection
through nonselective free radical scavenging. As described
above for agents such as amifostine, selective uptake or ac-
tivityintumortissueisessentialtorealizeagaininthether-
apeutic ratio.
A number of trials have been performed with antioxi-
dants delivered during the course of radiotherapy, with the
goal of reducing normal tissue toxicity, in many instances
with promising results. For example, antioxidants have
been delivered concurrently during the course of radiother-
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Figure 4. T1-weighted MRI images using tempol. (A): Schematic diagram of the placement of a tumor-bearing mouse in a res-
onator and the MRI slice selected that includes normal muscle tissue, the salivary gland region, and the tumor in the contralateral
leg. (B): T2-weighted MR image of the selected slice before injecting tempol to ensure that the target tissues were in the field of
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Adapted from Cotrim AP, Hyodo F, Matsumoto K et al. Differential radiation protection of salivary glands versus tumor by
Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging. Clin Cancer Res 2007;13:4928–4933,
with permission.
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nary fibrosis [30], cystitis [31], and alopecia [32]. With this
approachofdeliveringtheantioxidantsconcurrently,tumor
protection has been raised as a major concern [33].
Unfortunately, the use of antioxidant vitamins, such as
alpha tocopherol and beta carotene, during the course of ra-
diotherapy was associated with evidence of poorer tumor
control in randomized trials [28, 34]. The lower toxicity as-
sociated with the use of these agents is appealing, but not at
the cost of poorer tumor control. These findings reinforce
the importance of preclinical testing of radioprotectors to
verify a lack of tumor protection. Regardless of the extent
of preclinical evidence supporting a lack of tumor protec-
tion, clinical trials testing new radioprotectors should care-
fullydocumenttumorcontrol.Topicalapplicationhasbeen
used to minimize the possibility of systemic absorption and
interference with tumor response to radiation [32]; how-
ever, caution is advised because even topical applications
for the prevention of mucositis in head and neck cancers
havebeenassociatedwithevidenceofpoorertumorcontrol
[29].
When discussing antioxidants as radioprotectors, it is
worth mentioning the use of SOD as a method to prevent
radiotherapy-induced toxicity. Ionizing radiation results in
theformationofsuperoxideradicalsthatarehighlyreactive
andpotentiallydamagingtocells.SODisanenzymethatis
naturallypresentinhumancells.Itcatalyzestheconversion
of superoxide to oxygen and hydrogen peroxide and func-
tions as an antioxidant during normal conditions and after
radiation.
Intracellular localization of SOD is critical to its effec-
tiveness as an antioxidant; however, SOD is a large protein
and does not freely enter into cells. To circumvent this lim-
itation, much of the work evaluating SOD as a radioprotec-
tor has used gene therapy to increase the levels of SOD in
tissues to be irradiated to prevent or decrease radiation-
induced mucositis [35], esophagitis [36], pneumonitis [37–
39], and fibrosis [40, 41] in animal models. Importantly,
studies of tumor response after these delivery methods [39]
andstudiesoftumorcelllinesexpressingvariousquantities
of manganese SOD have been completed and suggest that
this therapy does not decrease tumor response to radiation
[42].Additionalworkneedstobecompletedtodetermineif
these findings can be successfully translated into clinical
trials.
Nonantioxidant Radioprotectors
Efforts to reduce early or late toxicities of radiotherapy
have led to the development of a number of agents that can
bedeliveredbeforeoratthetimeofradiotherapytoenhance
the survival of critical cell compartments. These agents do
not fit the description of a chemical radioprotector but do
prevent radiation-induced cell death and can thus be de-
scribed as radioprotectors.
One example of such an agent is the hormone melato-
nin.Melatoninisthoughttoactasanantioxidantitself[43–
45], but also acts to increase the expression of antioxidant
enzymes such as SOD and glutathione peroxidase [46, 47].
Radioprotection with melatonin and melatonin analogs has
been documented in a number of animal models [48–53].
Importantly, melatonin has also been shown to have direct
antitumor effects [54] and has been described as a radiation
sensitizer for tumors in animal models [55].
The use of melatonin as a radiation sensitizer for tumor
cells and as a radioprotector for normal cells was tested
clinically in a phase II Radiation Therapy Oncology Group
trial [56]. In that study, patients were randomized to either
morning or nighttime high-dose melatonin during radio-
therapy. Melatonin was continued after radiotherapy until
progression or until 6 months. Although melatonin deliv-
ered concurrently with radiation was well tolerated, there
was no evidence that the treatment resulted in a longer sur-
vival time or better neurologic function than in historical
controls.
Targeting signal transduction pathways has also been
explored as a mechanism to protect organisms and tis-
sues from ionizing radiation. One example of this ap-
proach is the use of the polypeptide CBLB502 [57],
whichbindstoandactivatesToll-likereceptor5(TLR5),
which is expressed in enterocytes [58] and intestinal en-
dothelial cells [59]. Activation of TLR5 results in acti-
vation of nuclear factor B, which is thought to play an
important role in the response of the intestine to irradia-
tion[60].DeliveryofCBLB502priortoandshortlyafter
radiation protected mice and rhesus monkeys from lethal
total body irradiation, with evidence of less damage to
the intestine and bone marrow [57]. Importantly, no ev-
idence of tumor protection from irradiation was evident.
It is possible that this type of protector could be useful
not only for accidental exposures but also for therapeutic
radiation, when large areas of intestine or marrow could
be considered dose limiting.
Radiation Mitigators
Radiation-induced late normal tissue toxicity is increas-
ingly being appreciated as a phenomenon of ongoing
changes in tissue after radiation but prior to the manifesta-
tion of toxicity. These events include ongoing mitotic cell
deathandperpetuallyactivecytokinecascadesthatcanlead
to vascular damage, tissue hypoxia, and excessive extracel-
lular matrix deposition [61]. Radiation mitigators aim to
interrupt these cascades or intervene to prevent the perpet-
366 Radiation-Induced Normal Tissue Injuryuationofdamageandthusreducetheexpressionoftoxicity.
Alternatively, radiation mitigators can be agents delivered
during or shortly after exposure to repopulate a critical cell
compartment such as the mucosa or bone marrow. In this in-
stance, the mitigator is used to prevent acute toxicity. For ra-
diologic terrorism and space research, much of the focus of
mitigatorshasbeeninthefieldofdevelopingchemopreventa-
tivestoreducecarcinogenesisoftotalbodyexposures.Table1
summarizes several promising radiation mitigators [16, 62–
82]. A few examples are discussed in detail below.
Many cytokines and growth factors are radiation
mitigators when used near the time of radiation. These
agents stimulate the differentiation of stem cells in bone
marrow or the intestine, thus preventing bone marrow
failure or gastrointestinal syndrome after total body ex-
posure. A number of cytokines and growth factors have
been explored as radioprotectors/mitigators. For exam-
ple, G-CSF can effectively reduce the lethality of total
body radiation exposure by assisting in marrow recovery
[83, 84]. Recently, interest in keratinocyte growth factor
(KGF) as a possible mitigator has spurred both preclini-
cal studies and clinical trials.
KGF is a growth factor that stimulates a number of cel-
lular processes such as differentiation, proliferation, DNA
repair, and detoxification of reactive oxygen species [78].
These properties make KGF an attractive method to stimu-
late the recovery of mucosa after ionizing radiation. Ac-
cordingly, delivery of KGF in animal models prevents
radiation-induced xerostomia [79] and mucositis [85].
Palifermin is a recombinant human KGF that is ap-
proved for use in decreasing the incidence and duration of
severe oral mucositis in patients with hematologic malig-
nancies who receive high doses of chemotherapy and radi-
ation therapy followed by stem cell rescue. The success of
palifermininpatientswithmucositisaftercytotoxictherapy
[86] led to attempts to evaluate its use in patients with head
and neck cancers receiving chemoradiotherapy, in whom
mucositis can be severe and prolonged.
Evaluation of palifermin in a phase II clinical trial as
a method to reduce mucositis in patients receiving radi-
Table 1. Representative radiation mitigators
Class
Representative
agent(s) Proposed mechanism Use Clinical status [62]
Growth factor Palifermin Stimulates differentiation, proliferation,
DNA repair, and detoxification of
reactive oxygen species [78]
Mitigation of mucositis
[16], mitigation of
xerostomia [79]
In use to prevent or reduce
mucositis after transplantation;
ongoing testing with radiation,
chemotherapy, or both to
prevent mucositis
Protease inhibitor Bowman-Birk
proteinase inhibitor
DNA repair: increases fidelity of and
stimulates DNA repair [63–65]
Chemopreventative
[66], antifibrotic [67]
Ongoing testing as a
chemopreventative
Dithiolthione Oltipraz Increased nonprotein sulfhydryl in
cells: enhances radiation-inducible
glutathione S-transferase and
microsomal epoxide hydrolase
expression
Chemopreventative,
protector against total
body exposures [68]
Ongoing testing as a
chemopreventative
ACE inhibitor Captopril, enalapril,
ramipril
Inhibition of angiotensin II production,
suppression of proliferation, inhibition
of nitric oxide synthase, prevention of
radiation-induced TGF-, suppression
of chronic oxidative stress, suppression
of aldosterone [69]
Prevention of
radiation-induced
nephropathy [70], optic
neuropathy [71], and
pneumonitis [72]
Ongoing and recently completed
clinical trials for prevention of
radiation-induced nephropathy
and pneumonitis; clinical data
available suggesting
stabilization of renal function in
established radiation-induced
nephropathy [69]
Isoflavone Genistein Hematopoietic stem cell quiescence
[69], tyrosine kinase inhibitor [73],
antioxidant
Chemopreventative,
protector against total
body exposures [74]
Ongoing testing as a
chemopreventative, direct
anticancer agent, radiation
sensitizer in tumor tissue
Hmg-CoA reductase
inhibitors (statins)
Simvastatin, pravastatin,
lovastatin
Inhibition of the
Rho/CCN2/extracellular matrix cascade
[75]
Mitigation of radiation
enteropathy [76],
pulmonary fibrosis [77]
Ongoing trials testing as a
mitigator of rectal injury with
radiation, testing as a
chemopreventative
COX2 inhibitors/NSAIDs Celecoxib, aspirin,
ibuprofen,
Inhibits COX2 activity in the setting of
increased COX2 expression and
prostaglandin synthesis after radiation
[80]
Radiation sensitizer
[81],
chemopreventative
[82], mitigator of
mucositis
Ongoing trials as a
chemopreventative, ongoing and
completed trials as a radiation
sensitizer for tumors, ongoing
trials for prevention of mucositis
TGF- signaling inhibitors Halofuginone, 1D11,
SM16
Inhibits TGF- signaling that results in
activation of profibrotic pathways
Antifibrotic Ongoing clinical trials in disease
characterized by fibrosis
Abbreviations: ACE, angiotensin-converting enzyme; COX2, cyclooxygenase 2; Hmg-CoA, 3-hydroxy-3-methyl-glutaryl-
coenzyme A; NSAIDs, nonsteroidal anti-inflammatory drugs; TGF, transforming growth factor.
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find significantly less mucositis, dysphagia, or xerosto-
miawiththeagentthanwithplacebowhenevaluatingthe
total study population; however, patients who received
hyperfractionated radiotherapy had a lower incidence of
mucositis and a shorter duration of mucositis [87]. A
number of methodological problems led investigators to
conclude that future studies should employ standardized
tools for the assessment of mucositis, increase the dura-
tion of assessments to ensure that this period encom-
passes the resolution of mucositis in most patients, and
use higher doses of palifermin. Because normal mucosa
and squamous tumors may express the receptor for KGF,
the investigators simultaneously reported the long-term
follow-up of survival and progression-free survival out-
comes in this study, showing that the delivery of palifer-
min did not influence disease control.
Mitigatorsoflateradiationdamagefrequentlytargetra-
diation fibrosis, a common and potentially debilitating
complication of therapeutic radiotherapy. A variety of
agents that protect against fibrosis have been evaluated as
mitigatorsofradiationfibrosis.Transforminggrowthfactor
(TGF)- plays a critical role in the development of radia-
tion-induced fibrosis. It is therefore not surprising that
many of the agents that have been used to prevent the de-
velopment of radiation fibrosis directly or indirectly inhibit
the TGF- signaling pathway.
TGF-  receptor inhibition has shown the ability to pre-
ventlungfibrosisafterradiationexposureinanimalmodels
[88, 89]. An alternative mechanism is the use of halofugi-
none, a small molecule that inhibits TGF- signaling,
which has been shown in animal models to inhibit radia-
tion-induced fibrosis [90]. Many of these agents are inter-
esting for possible translation into the clinical setting;
however, given the important role of TGF- in tumor dor-
mancy, progression, and metastasis [91], a thorough evalu-
ation of tumor protection with these strategies is obviously
important to ensure safe clinical translation.
CONCLUSIONS AND FUTURE DIRECTIONS
Radiation therapy is frequently used in the definitive man-
agement and palliative care of patients with cancer. Treat-
ment of tumor tissue inevitably results in the irradiation of
surrounding normal tissues. Acute and late radiation-in-
duced normal tissue toxicity can have a significant impact
on compliance with therapy and quality of life. Technolog-
ical advances may result in lower normal tissue exposure,
butitisexpectedthattechnologicapproacheswillnotcom-
pletely prevent toxicity in irradiated fields.
The use of compounds to protect normal tissues or min-
imize toxicity after damage has occurred may provide the
ability to reduce toxicity for patients treated with radiother-
apy and may provide methods to treat individuals exposed
toradiationthroughterrorism.Evidenceofefficacy,lackof
tumor protection, and acceptable toxicity are all important
considerations for developing these agents. Amifostine re-
mains the only agent currently in clinical use as a radiopro-
tector. A number of other candidate compounds, such as
tempol, will be tested in future years as a way to reduce ra-
diation-induced normal tissue toxicity and complications.
Although prevention of radiation toxicity may provide
the best opportunity to minimize impact on quality of life,
few radioprotectors are in clinical use and the treatment of
radiation injury remains an important mechanism to deal
with radiation-induced toxicity. Antifibrotic treatments, such
as pentoxyfilline and vitamin E, have shown promise in clin-
ical trials. Newer technologies, such as gene therapy, may of-
fer the ability to reverse radiation-induced toxicities such as
xerostomia[92].Technologicimprovementsandthedevelop-
mentofradioprotectors,mitigators,andtreatmentsfortoxicity
are all important areas of research as methods for improving
quality of life in patients who have received radiotherapy.
FINAL COMMENT
The distinguished clinician/scientist who is honored and
recognized by this special issue, Dr. Eli Glatstein, is a true
champion of translational research. In fact, he was practic-
ingtranslationalresearchlongbeforethetermbecamepop-
ular. While Eli never considered himself a bench scientist,
he was constantly probing the radiation biology literature
for novel approaches to treating cancer. His conviction to
translate laboratory findings to clinical trials was influ-
enced by two major figures in radiation oncology and biol-
ogy, Henry Kaplan and Jack Fowler, under whom Eli
trained. Eli often quoted Kaplan, “If you want to treat
Hodgkin’s disease you have to think like a Reed Sternberg
cell,” emphasizing the need and necessity of understanding
the biology to effectively treat the cancer. From Jack
Fowler, he acquired two fundamental traits, enthusiasm for
research (and life) and the talent for diplomatically and ef-
fectively questioning established dogma. Eli does not shy
away from addressing tough issues. In thought-provoking
editorials over the years on a variety of topics, Eli has es-
tablished himself as the conscience of the radiation oncol-
ogy community.
Not only is Eli an accomplished experimental radiation
oncologist, but he is also a well-rounded oncologist in gen-
eral. Eli has participated in and contributed to countless
rounds in surgery and medical oncology, positively influ-
encing a younger generation of oncologists and crystalliz-
ing ideas for future translational studies involving
multidisciplinaryapproachestocancertreatment.Through-
368 Radiation-Induced Normal Tissue Injuryout his career, Eli has consistently embraced the concept
that an in-depth understanding of the biology of cancer is
the correct path toward improving cancer treatment. His
support and dedication to this concept is appreciated by all
of those who have been fortunate to work with him.
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